NDAORALTABLET, EXTENDED RELEASE1 Generic Approved
Approved
Feb 2005
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDURA XL is an extended-release oral tablet containing doxazosin mesylate, a selective alpha-1 adrenergic receptor antagonist approved for benign prostatic hyperplasia (BPH). It reduces urinary symptoms by blocking smooth muscle tone in the prostate and bladder neck, improving urine flow and decreasing frequency, nocturia, and hesitancy. The drug addresses both the dynamic functional component of BPH rather than relying on static prostate size reduction.
$0.804MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending signals a contracting franchise likely managed by a lean commercial team focused on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
Started May 2009
989 enrolled
Prostatic Hyperplasia
Career Relevance
CARDURA XL offers limited career growth due to LOE status and minimal linked job openings; roles focus on defending market share against generics and managing brand transition. Assignment to this product is typically a consolidation or operational role rather than a high-visibility growth opportunity.
Brand Manager
Worked on CARDURA XL at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.